Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Hot topics

AZD0780: A small molecule inhibitor of PCSK9 – Early clinical data

AZD0780: A small molecule inhibitor of PCSK9 – Early clinical data

Reports from the 21st Virtual Closed Scientific Expert Meeting of the Editorial Board Rick Vega  

read more »
Posted on 23 October 2024 | Posted by Rick Vega | Posted in Hot topics, 21st Closed Scientific Expert Meeting of the Editorial Board
Lerodalcibep, a third generation PCSK9 inhibitor: Overview of completed phase 3 programme

Lerodalcibep, a third generation PCSK9 inhibitor: Overview of completed phase 3 programme

Reports from the 21st Virtual Closed Scientific Expert Meeting of the Editorial Board Dirk Blom

read more »
Posted on 23 October 2024 | Posted by Dirk Blom | Posted in Hot topics, 21st Closed Scientific Expert Meeting of the Editorial Board
The trajectory of ASCVD: Focus on subclinical atherosclerosis

The trajectory of ASCVD: Focus on subclinical atherosclerosis

Reports from the 21st Virtual Closed Scientific Expert Meeting of the Editorial Board Borja Ibanez

read more »
Posted on 23 October 2024 | Posted by Borja Ibanez | Posted in Hot topics, 21st Closed Scientific Expert Meeting of the Editorial Board
Post-ACS therapeutic strategies: What has changed?

Post-ACS therapeutic strategies: What has changed?

Reports from the 20th Virtual Closed Scientific Expert Meeting of the Editorial Board  Matthew Budoff

read more »
Posted on 7 May 2024 | Posted by Matthew Budoff | Posted in Hot topics, 20th Closed Scientific Expert Meeting of the Editorial Board
CRISPR engineering of wild-type alleles versus millions of years of human evolution

CRISPR engineering of wild-type alleles versus millions of years of human evolution

Reports from the 20th Virtual Closed Scientific Expert Meeting of the Editorial Board  Steven Farber

read more »
Posted on 7 May 2024 | Posted by Steven Farber | Posted in Hot topics, 20th Closed Scientific Expert Meeting of the Editorial Board
The statin intolerant patient with ASCVD: What is your therapeutic strategy?

The statin intolerant patient with ASCVD: What is your therapeutic strategy?

Reports from the 20th Virtual Closed Scientific Expert Meeting of the Editorial Board  Ioanna Gouni-Berthold

read more »
Posted on 7 May 2024 | Posted by Ioanna Gouni-Berthold | Posted in Hot topics, 20th Closed Scientific Expert Meeting of the Editorial Board
PCSK9 inhibition with a novel fusion protein

PCSK9 inhibition with a novel fusion protein

Reports from the 20th Virtual Closed Scientific Expert Meeting of the Editorial Board  Frederick Raal

read more »
Posted on 2 May 2024 | Posted by Frederick J. Raal | Posted in Hot topics, 20th Closed Scientific Expert Meeting of the Editorial Board
Oral PCSK9 inhibition: Clinical update

Oral PCSK9 inhibition: Clinical update

Reports from the 20th Virtual Closed Scientific Expert Meeting of the Editorial Board  Christie Ballantyne

read more »
Posted on 2 May 2024 | Posted by Christie Ballantyne | Posted in Hot topics, 20th Closed Scientific Expert Meeting of the Editorial Board
What do you do after a Statin? So many choices… what is yours?

What do you do after a Statin? So many choices… what is yours?

Reports from the 19th Virtual Closed Scientific Expert Meeting of the Editorial Board  Anne Goldberg

read more »
Posted on 8 February 2024 | Posted by Anne Goldberg | Posted in Closed Scientific Expert Meetings of the Editorial Board, 19th Closed Scientific Expert Meeting of the Editorial Board, Hot topics
Keynote – HDL and PCSK9: Going for a ride?

Keynote – HDL and PCSK9: Going for a ride?

Reports from the 19th Virtual Closed Scientific Expert Meeting of the Editorial Board  Manuel Mayr

read more »
Posted on 19 October 2023 | Posted in Closed Scientific Expert Meetings of the Editorial Board, 19th Closed Scientific Expert Meeting of the Editorial Board, Hot topics
PCSK9 targeting: Inside versus outside?

PCSK9 targeting: Inside versus outside?

Reports from the 19th Virtual Closed Scientific Expert Meeting of the Editorial Board  Alberto Corsini

read more »
Posted on 19 October 2023 | Posted by Alberto Corsini | Posted in Closed Scientific Expert Meetings of the Editorial Board, 19th Closed Scientific Expert Meeting of the Editorial Board, Hot topics
Statins and PCSK9 inhibitors in combination: Initial therapy in very high-risk patients in secondary prevention

Statins and PCSK9 inhibitors in combination: Initial therapy in very high-risk patients in secondary prevention

Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board  Alberto Zambon 

read more »
Posted on 5 July 2023 | Posted by Alberto Zambon | Posted in Hot topics, 18th Closed Scientific Expert Meeting of the Editorial Board
Elevated LDL-C and elevated Lp(a) with recurrent MACE: What to do, to do what?

Elevated LDL-C and elevated Lp(a) with recurrent MACE: What to do, to do what?

Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board  Erik Stroes 

read more »
Posted on 21 June 2023 | Posted by Erik Stroes | Posted in Hot topics, 18th Closed Scientific Expert Meeting of the Editorial Board
Aortic valve stenosis: A key pathophysiological role for Lp(a)?

Aortic valve stenosis: A key pathophysiological role for Lp(a)?

Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board  Benoit Arsenault 

read more »
Posted on 21 June 2023 | Posted by Benoit Arsenault | Posted in Hot topics, 18th Closed Scientific Expert Meeting of the Editorial Board
Lp(a) and plaque progression: Insights from imaging

Lp(a) and plaque progression: Insights from imaging

Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board  Marc Dweck 

read more »
Posted on 8 June 2023 | Posted by Marc Dweck | Posted in Hot topics, 18th Closed Scientific Expert Meeting of the Editorial Board
LDL-C lowering with PCSK9 inhibition: Multi-modal imaging and impact on coronary plaque in ACS patients

LDL-C lowering with PCSK9 inhibition: Multi-modal imaging and impact on coronary plaque in ACS patients

Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board  Stephen Nicholls 

read more »
Posted on 8 June 2023 | Posted by Steve Nicholls | Posted in Hot topics, 18th Closed Scientific Expert Meeting of the Editorial Board
siRNA-mediated lowering of Lp(a) by Olpasiran

siRNA-mediated lowering of Lp(a) by Olpasiran

Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board  Michael Koren 

read more »
Posted on 11 January 2023 | Posted by Michael Koren | Posted in Hot topics, 17th Closed Scientific Expert Meeting of the Editorial Board
A new ASO PCSK9 inhibitor: The Etesian study

A new ASO PCSK9 inhibitor: The Etesian study

Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board  Alexis Hofherr 

read more »
Posted on 16 December 2022 | Posted by Alexis Hofherr | Posted in Hot topics, 17th Closed Scientific Expert Meeting of the Editorial Board
ASO-mediated reduction in Lp(a) levels: Update on Pelacarsen

ASO-mediated reduction in Lp(a) levels: Update on Pelacarsen

Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board  Sotirios Tsimikas 

read more »
Posted on 16 December 2022 | Posted by Sotirios Tsimikas | Posted in Hot topics, 17th Closed Scientific Expert Meeting of the Editorial Board
siRNA-mediated lowering of Lp(a) by SLN360

siRNA-mediated lowering of Lp(a) by SLN360

Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board  Steve Nissen 

read more »
Posted on 16 December 2022 | Posted by Steve Nissen | Posted in Hot topics, 17th Closed Scientific Expert Meeting of the Editorial Board

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.
Educational Partners and Supporters
AstraZeneca AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation
Lib Therapeutics Novartis Sanofi
© Copyright 2024 PCSK9 Forum. All rights reserved